Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
- Autores
- Van Deun, A.; Barrera, Lucía; Bastian, I.; Fattorini, L.; Hoffmann, H.; Kam, Kai Man; Rigouts, Leen; Ruesch-Gerdes, S.; Wright, A.
- Año de publicación
- 2009
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.
Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.
Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia.
Fil: Fattorini, L. Istituto Superiore di Sanita; Italia.
Fil: Hoffmann, H. IML-Gauting; Alemania.
Fil: Kam, K. M. Centre for Health Protection; China.
Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania.
Fil: Wright, A. World Health Organization; Suiza. - Fuente
- Journal of Clinical Microbiology, 2009, 47(11), 3501–3506.
- Materia
-
Mycobacterium tuberculosis
Rifampin - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:Publications/123456789/294
Ver los metadatos del registro completo
id |
SGCANLIS_72ccef3a90b04a29055741319abe1e9f |
---|---|
oai_identifier_str |
oai:sgc.anlis.gob.ar:Publications/123456789/294 |
network_acronym_str |
SGCANLIS |
repository_id_str |
a |
network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
spelling |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test ResultsVan Deun, A.Barrera, LucíaBastian, I.Fattorini, L.Hoffmann, H.Kam, Kai ManRigouts, LeenRuesch-Gerdes, S.Wright, A.Mycobacterium tuberculosisRifampinThe objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia.Fil: Fattorini, L. Istituto Superiore di Sanita; Italia.Fil: Hoffmann, H. IML-Gauting; Alemania.Fil: Kam, K. M. Centre for Health Protection; China.Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania.Fil: Wright, A. World Health Organization; Suiza.2009info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1098-660Xhttp://jcm.asm.org/content/47/11/3501.full.pdf+htmlhttp://sgc.anlis.gob.ar/handle/123456789/294Journal of Clinical Microbiology, 2009, 47(11), 3501–3506.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISenginfo:eu-repo/semantics/openAccess2025-09-04T11:15:39Zoai:sgc.anlis.gob.ar:Publications/123456789/294Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:15:39.647Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
dc.title.none.fl_str_mv |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
title |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
spellingShingle |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results Van Deun, A. Mycobacterium tuberculosis Rifampin |
title_short |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
title_full |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
title_fullStr |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
title_full_unstemmed |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
title_sort |
Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results |
dc.creator.none.fl_str_mv |
Van Deun, A. Barrera, Lucía Bastian, I. Fattorini, L. Hoffmann, H. Kam, Kai Man Rigouts, Leen Ruesch-Gerdes, S. Wright, A. |
author |
Van Deun, A. |
author_facet |
Van Deun, A. Barrera, Lucía Bastian, I. Fattorini, L. Hoffmann, H. Kam, Kai Man Rigouts, Leen Ruesch-Gerdes, S. Wright, A. |
author_role |
author |
author2 |
Barrera, Lucía Bastian, I. Fattorini, L. Hoffmann, H. Kam, Kai Man Rigouts, Leen Ruesch-Gerdes, S. Wright, A. |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Mycobacterium tuberculosis Rifampin |
topic |
Mycobacterium tuberculosis Rifampin |
dc.description.none.fl_txt_mv |
The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains. Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica. Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina. Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia. Fil: Fattorini, L. Istituto Superiore di Sanita; Italia. Fil: Hoffmann, H. IML-Gauting; Alemania. Fil: Kam, K. M. Centre for Health Protection; China. Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica. Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania. Fil: Wright, A. World Health Organization; Suiza. |
description |
The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 |
dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
1098-660X http://jcm.asm.org/content/47/11/3501.full.pdf+html http://sgc.anlis.gob.ar/handle/123456789/294 |
identifier_str_mv |
1098-660X |
url |
http://jcm.asm.org/content/47/11/3501.full.pdf+html http://sgc.anlis.gob.ar/handle/123456789/294 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
Journal of Clinical Microbiology, 2009, 47(11), 3501–3506. reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
instacron_str |
ANLIS |
institution |
ANLIS |
repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
_version_ |
1842344418340765696 |
score |
12.623145 |